20/11/2014 - 14:59
BOSTON – Secukinumab showed enduring efficacy in ankylosing spondylitis after 52 weeks of treatment, based on data reported at the annual meeting of the American College of Rheumatology.
The...
Field of Interest: Rheumatology
Categories:
News Feed: Internal Medicine News - Rheumatology